Sun Pharma Advanced Research Company Limited (NSE:SPARC)
India
· Delayed Price · Currency is INR 124.48
-1.62 (-1.28%)
Mar 12, 2025, 3:30 PM IST
NSE:SPARC Revenue
Sun Pharma Advanced Research Company had revenue of 149.10M INR in the quarter ending December 31, 2024, with 7.58% growth. This brings the company's revenue in the last twelve months to 611.35M, down -42.69% year-over-year. In the fiscal year ending March 31, 2024, Sun Pharma Advanced Research Company had annual revenue of 755.45M, down -68.36%.
Revenue (ttm)
611.35M
Revenue Growth
-42.69%
P/S Ratio
66.08
Revenue / Employee
1.49M
Employees
409
Market Cap
40.40B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 755.45M | -1.63B | -68.36% |
| Mar 31, 2023 | 2.39B | 1.02B | 73.98% |
| Mar 31, 2022 | 1.37B | -1.16B | -45.74% |
| Mar 31, 2021 | 2.53B | 1.76B | 229.31% |
| Mar 31, 2020 | 768.14M | -1.06B | -57.99% |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 516.03B |
| Divi's Laboratories | 90.78B |
| Cipla | 267.20B |
| Mankind Pharma | 116.41B |
| Zydus Lifesciences | 222.47B |
| Apollo Hospitals Enterprise | 211.46B |
| Aurobindo Pharma | 309.22B |
| Alkem Laboratories | 127.57B |
Sun Pharma Advanced Research Company News
- 3 months ago - SPARC signs binding LOI with UCSF and Tiller Therapeutics for pre-clinical oncology asset - Business Upturn
- 4 months ago - Sun Pharma Advanced Research Q2 revenue at Rs 12.86 crore; net loss widens to Rs 107.33 crore - Business Upturn